AI Article Synopsis
- The study investigated how the Sharp score relates to demographic factors and immune-inflammatory markers in patients with rheumatoid arthritis (RA) who also have anemia.
- It analyzed clinical data from over 2,000 RA patients to identify correlations between the Sharp score and various influencing factors, finding notable relationships.
- Results indicated that anemia affects about half of RA patients, with certain factors like age, gender, and specific blood markers increasing the Sharp score, suggesting the need for tailored treatment strategies for these patients.
Article Abstract
Objective: This study examined the relationship of the Sharp score with demographic factors and clinical immune-inflammatory markers in patients with anemia in rheumatoid arthritis (RA).
Methods: The clinical data of 1057 patients with RA and anemia and 1006 patients with RA without anemia were retrospectively analyzed. Spearman's correlation coefficient analysis, association rule analysis, and logistic regression were used to study the relationships between the Sharp score and influencing factors in patients with RA and anemia.
Results: The incidence of anemia was 51.24% (1057/2063), and mild anemia accounted for 81.93% (866/1057) of cases. Spearman's correlation coefficient and association rule analyses revealed that the Sharp score of patients with RA and anemia was correlated with immune-inflammatory response and anemia. Logistic regression analysis illustrated that advanced age (>60 years), female, low serum iron levels, C-reactive protein positivity, and immunoglobulin A positivity were risk factors for a high Sharp score (>28.25) in patients with RA and anemia.
Conclusion: The Sharp score is closely related to clinical disease activity and anemia, and it should be considered in the treatment strategy of patients with RA and anemia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969521 | PMC |
| http://dx.doi.org/10.1177/03000605221088560 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retinal oculomics and risk of incident aortic aneurysm and aortic adverse events: a population-based cohort study.
Int J Surg
January 2025
School of Medicine, South China University of Technology, Guangzhou, China.
Background: The asymptomatic onset and extremely high mortality rate of aortic aneurysm (AA) highlight the urgency of early detection and timely intervention. The alteration of retinal vascular features (RVFs) can reflect the systemic vascular properties, and be widely used as the biomarker for cardiovascular disease risk prediction. Therefore, we aimed to investigate associations of RVFs with AA and its progression.
View Article and Find Full Text PDFKnowledge and attitude of nosocomial infection prevention and control precautions among healthcare personnel at Kiruddu Referral Hospital in Kampala, Uganda.
BMC Health Serv Res
January 2025
Department of Biological Sciences, Faculty of Science, Kyambogo University, Kampala, Uganda.
Background: A key concern for global public health is nosocomial infections. Essential to the fight against nosocomial infection, is healthcare professionals' knowledge and attitudes. Therefore, this study investigated healthcare professionals' knowledge and attitudes toward nosocomial infection at the Kiruddu Referral Hospital, Kampala, Uganda.
View Article and Find Full Text PDFLenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan.
J Cancer Res Clin Oncol
January 2025
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Purpose: Atezolizumab-bevacizumab (AB) is the established first-line systemic therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, the optimal second-line treatment for patients unresponsive to AB remains undefined.
Patients And Methods: This multicenter, retrospective study included patients with uHCC who underwent second-line treatment with lenvatinib (LEN) or sorafenib (SOR) after AB failure at two academic centers between June 2018 and November 2023.
The prevalence of PD-L1 expression in patients with advanced oesophageal cancer: the EXCEED observational study.
J Clin Pathol
January 2025
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Aims: There are limited data on programmed death ligand 1 (PD-L1) expression in oesophageal cancer (OC) from multicentre studies conducted across China. We aimed to determine the prevalence of high PD-L1 expression in patients with advanced OC.
Methods: The EXCEED study was a multicentre, retrospective analysis of data from six tertiary hospitals that evaluated PD-L1 expression in adults with advanced OC or advanced head and neck squamous cell carcinoma.
Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial.
Cell Transplant
January 2025
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
To assess the impact of a single intra-articular (IA) injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with knee osteoarthritis (OA), a randomized, double-blind, placebo-controlled study was conducted. The study included 24 patients with knee OA who were randomly assigned to receive either a single IA injection of BM-MSCs or normal saline. Changes in the visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Knee Injury and Osteoarthritis Outcome Score (KOOS) after IA injection were assessed at 3, 6, 9, and 12 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!